EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access

Hydrogen sulfide: Recent development of its dual donors and hybrid drugs

Shi Xu, Meg Shieh iD, Bindu D Paul iD, Ming Xian

British Journal of Pharmacology · 2026-01 · 183 (1) · 70-82

DOI: 10.1111/bph.16211 ↗

At a glance

Übersichtsarbeit in British Journal of Pharmacology, 2023-09. Written by Shi Xu and 3 co-authors. Institution: Department of Chemistry, Brown University, Providence, Rhode Island, USA. Major MEDLINE topics: Hydrogen Sulfide. Cited 25 times so far (Crossref); 91 references. The full text is freely available in PubMed Central. Funded by: NIA NIH HHS, NIH HHS, NHLBI NIH HHS.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Hydrogen sulfide (H 2 S) is an important gaseous signalling molecule known to be critically involved in regulating cellular redox homeostasis. As the beneficial and therapeutic effects of H 2 S in pathophysiology, such as in cardiovascular and neurodegenerative diseases, have emerged, so too has the drive for the development of H 2 S‐releasing compounds (aka donors) and their therapeutic applications. Most reported donor compounds singularly release H 2 S through biocompatible triggers. An emerging area in the field is the development of compounds that can co‐deliver H 2 S with other drugs or biologically relevant species, such as reactive oxygen and nitrogen species (ROS and RNS, respectively). These H 2 S‐based dual donors and hybrid drugs are expected to offset negative side effects from individual treatments or achieve synergistic effects rendering them more clinically effective. Additionally, considering that molecules exist and interact physiologically, dual donors may more accurately mimic biological systems as compared to single donors and allow for the elucidation of fundamental chemistry and biology. This review focuses on the recent advances in the development of H 2 S‐based dual donors and hybrid drugs along with their design principles and synergistic effects. LINKED ARTICLES This article is part of a themed issue Recent Innovations in Targeting Redox Biology for Therapeutics. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.1/issuetoc

Subjects

MeSH terms (MEDLINE)

Hydrogen SulfideHumansAnimalsDrug DevelopmentOxidation-Reduction

Author keywords

donorsdual donorsgasotransmittershybrid drugshydrogen sulfidenitric oxide

Substances

Hydrogen Sulfide

Authors and institutions

  • Department of Chemistry, Brown University, Providence, Rhode Island, USA.
  • Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Lieber Institute for Brain Development, Baltimore, Maryland, USA.

ORCID profiles: Meg Shieh, Bindu D Paul

Funding

  • NIA NIH HHS
  • NIH HHS
  • NHLBI NIH HHS
  • NIGMS NIH HHS
  • NIDA NIH HHS
  • American Heart Association and Paul Allen Foundation Grant
  • National Institutes of Health

Cite

APA

Xu, S., Shieh, M., Paul, B. D., & Xian, M. (2026). Hydrogen sulfide: Recent development of its dual donors and hybrid drugs. British Journal of Pharmacology, 183(1), 70-82. https://doi.org/10.1111/bph.16211

Vancouver

Xu S, Shieh M, Paul BD, Xian M. Hydrogen sulfide: Recent development of its dual donors and hybrid drugs. British Journal of Pharmacology. 2026;183(1):70-82. doi:10.1111/bph.16211

BibTeX
@article{Xu2026,
  author = {Xu, Shi and Shieh, Meg and Paul, Bindu D and Xian, Ming},
  title = {Hydrogen sulfide: Recent development of its dual donors and hybrid drugs},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {1},
  pages = {70--82},
  doi = {10.1111/bph.16211}
}
Start for free →